Can-Fite Biopharma Ltd Культура компании

Dr. Ilan Cohen, Ph.D. is Co-Founder of Can-Fite BioPharma Ltd. and served as its President and Chief Operating Officer. Dr. Cohen is a Patent Attorney and Senior Partner of Reinhold Cohn and Partners, Israel's largest intellectual property firm. He served as the Chief Executive Officer of Can-Fite BioPharma Ltd. until July, 2004. He has many years of experience in the biopharmaceutical field. Throughout his professional career, he gained extensive experience and expertise in business development in biotechnology field and build-up of intellectual property platforms into key business assets. He was also involved in the past in management of venture capital funds focused on investments in the life sciences industry. He has extensive business development experience and has deep strategic intellectual property understanding. He serves as Chairman of the Board at Feelter Sales Tools Ltd. He has been Chairman at Can-Fite BioPharma Ltd. since May 30, 2013 and served as its Vice Chairman from February 6, 2006 to May 30, 2013 and serves as its Director. He served a number of years as a Co-Chairman of the Biotech Committee of US-Israeli Science and Technology Commission. He has been a Director at OphthaliX Inc. (formerly Denali Concrete Management Inc.) since November 2011. Dr. Cohn serves as a Director of I.C.R.C. Management Ltd., a company wholly owned by him. He serves as Member of Advisory Board at alseT IP, LLC. He was the architect and builder of Can-Fite BioPharma 's intellectual property platform and managed to secure key patent licensing deals with the National Institute of Health (NIH) in the US and the Leiden University in the Netherlands, which led to the establishment of a multi-layered intellectual property platform that positions Can-Fite BioPharma as a leader in the therapeutic field of drugs that target the A3 adenosine receptor. He is a Member of the AIPPI (Israel Group), the FICPI (Israel Section), the Licensing Executive Society (LES) and serves on the Board of the Association of Israel Patent Attorneys. He serves as a Member of the Patent and Intellectual Property Rights Committee of the United States Israel Science and Technology Commission. He is one of the leading patent attorneys in Israel, with particular expertise in life sciences field. He was admitted to practice before the Israel Patent Office in 1989. Dr. Cohen has a Ph.D. in biology from the Hebrew University of Jerusalem.

Dr. Vibeke Strand, M.D., FACP, FACR (USA) serves as Senior Clinical Advisor of Drug Development at Can-Fite BioPharma Ltd. Dr. Strand serves as Biopharmaceutical Clinical and Regulatory Consultant with over twenty years experience in designing clinical development programs. She has been a Clinical rheumatologist for 35 years in a subspecialty practice in San Francisco, as a clinical investigator and subsequently as Director of Clinical Research at three pharmaceutical and biotech companies, prior to establishing her consulting practice in 1991. For eleven years, she has served as an Independent consultant to pharmaceutical and biotechnology companies, developing strategies for the efficient development of treatments for autoimmune diseases. She serves as Member of Scientific Advisory Board at Kypha Inc. She has been Member of Scientific Advisory Board at Protagen AG since December 10, 2015. She serves as a Member of Scientific Advisory Board of Chelsea Therapeutics International Ltd. (also known as Ivory Capital Corp). She served as a Member of Scientific Advisory Board of Anthera Pharmaceuticals, Inc. She serves as a Member of Advisory Board of Avidia, Inc. and Avidia Research Institute. She has been a Member of Scientific Advisory Board of ImmuPharma Plc since July 2013. She has been the Scientific Advisory Board of CORRONA since 2010. She serves as a Member of Advisory Board at Crescendo Bioscience, Inc. Dr. Strand served as a Member of Advisory Board at Alder Biopharmaceuticals Inc. until December 12, 2015. She served as a Member of Scientific Advisory Board at BioSeek Inc. She served as Member of Clinical Advisory Board of Can-Fite BioPharma Ltd. She served as a Member of the Autoimmune Disease Scientific Advisory Board at Idera Pharmaceuticals, Inc. since June 2008. She serves as Member of Advisory Panel at Logical Therapeutics, Inc. She has been a Member of the Cosmos Club since 1994. Dr. Strand has been an Adjunct Clinical Professor in the Division of Immunology and Rheumatology of Stanford University School of Medicine since September 2000 and Clinical Associate Professor since March 1993. She previously served as Assistant and Associate Clinical Professor at University of California San Francisco from 1981 to 1993. Her professional interests include development of outcome measures methodology and clinical and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases, including rheumatoid arthritis [RA], osteoarthritis [OA], fibromyalgia [FMS], gout, systemic lupus erythematosus [SLE] and systemic sclerosis [SSc]. She has served on numerous advisory panels including those at Amgen, Boehringer Ingelheim, Cypress Bioscience, GD Searle, Hoechst Marion Roussel, Hoffman La Roche, Novartis, RWJ Pharmaceuticals, Seragen, SmithKline Beecham, Vertex and Astra-Zeneca. Her commitment to promoting forums for the discussion of rational product development among industry, FDA and academia led to her establishment and co-chairing of the biyearly Innovative Therapies in Autoimmune Disease meetings from 1988 to 2007, organizing committee membership of the international Outcomes in Rheumatology Clinical Trials (OMERACT 1-11) consensus conferences from 1992 to 2004 and Co-chairing of OMERACT 7 in 2004. She has participated in the preparation of INDs for over 25 biologic and pharmaceutical agents, prepared and made advisory panel presentations for 6 NDAs and 4 BLAs. She was responsible for the phase III US clinical program and successful NDA submission for Arava (Aventis) in rheumatoid arthritis. She has assisted in preparation of applications, briefing documents and data presentation for defense of NDA and BLA applications in HIV, BMTx, CTCL, uveitis, RA, OA, FMS, gout and SLE. She helped found and co-chaired the Clinical Immunology Society Spring Fellows School from 2004 to 2008. Since 2005, she has served as a member of the Board of Directors of the Northern California Chapter of the Arthritis Foundation and their Medical and Scientific Committee, the Board of Directors of the Consortium of Rheumatology Researchers of North America: CORRONA from 2002 to 2008. Dr. Strand has been an invited speaker at FDA Arthritis Advisory Committee meetings discussing Guidance Documents for RA, OA, SLE, JRA, radiographic analyses in RA and pain from 1996 to 2003. She has authored over 300 original publications and reviews, 50 chapters, co-edited several books and multiple proceedings. She was one of eight in the first Primary Care Internal Medicine Residency at Michigan State University. She completed a Fellowship in Rheumatology/Immunology at the University of California, Francisco School of Medicine. She is a Fellow of the American College of Physicians in 1982, a Fellow of the American College of Rheumatology in 1986, serves on the Editorial board of several rheumatology journals. Dr. Strand earned her M.D. at the University of California San Francisco School of Medicine. She graduated from Swarthmore College with honors.

Dr. Michael H. Silverman, MD, FACP, FACR, serves as Medical Director of OphthaliX Inc. Dr. Silverman serves as Medical Director of Can-Fite BioPharma Ltd. He founded BioStrategics Consulting Ltd. and serves as its President. He has more than twenty five years pharmaceutical industry experience in clinical development with both international pharmaceutical companies and development stage biotechnology and biopharmaceutical companies. Dr. Silverman serves as the Head of Medical Affairs of Acretia, Inc., and a Trials Consultant of Innate Immunotherapeutics Limited (formerly Innate Therapeutics Limited (formerly Virionyx Corporation Ltd)). He serves as Clinical, Regulatory and Product Development Advisor of Angstrom Pharmaceuticals, Inc. He directs Angstrom's clinical trial programs. Dr. Silverman headed clinical research at Telor and Biopure, two biotechnology/small pharma start-up companies and was involved in management consulting in KPMG's Pharmaceutical Strategy group in 1997. Dr. Silverman is a recognized and accomplished expert in drug development and pharmaceutical clinical research. He directed clinical trials at the Sterling Winthrop Research Institute, managed therapeutics R&D at the Sandoz Research Institute. He serves as a Member of Scientific Advisory Board at Taiwan Liposome Company, Ltd. He serves as a Director of Bridgewell Inc. Dr. Silverman earned his MD degree from University of Chicago Pritzker School of Medicine. He completed his Internship and Medical Residency at the University of Iowa and a Fellowship in Rheumatology at the University of Colorado Medical Center.

Mr. Motti Farbstein has been Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Operating Officer and Financial Director. Mr. Farbstein served as Chief Operating Officer of Israel at Can-Fite BioPharma Ltd. He has managerial experience included seven years as Vice President of Mor Research Application (MRA). Mr. Farbstein has extensive experience in data management of clinical trials.